Standalone middle meningeal artery embolization versus Burr-hole surgery in nonacute subdural hematomas and selection strategy based on hematoma volume: A MAGIC-MT trial secondary analysis

Authors:

Abstract
Background and objectives: Middle meningeal artery embolization (MMAE) has emerged as an alternative technique with minimally invasive nature in nonacute subdural hematomas (NASDH). However, whether MMAE alone can replace burr-hole surgery (BHS) remains unclear. Methods: This exploratory secondary study used data from the MAGIC-MT randomized controlled trial to compare standalone MMAE and BHS. The primary outcomes were symptomatic recurrence and progression of hematomas. Overlap weighting (OW) was used to balance baseline variables between groups. Propensity score matching (PSM) was used as sensitivity analysis. Results: A total of 291 BHS and 77 MMAE patients were included. After balancing baseline features, the incidence of primary outcomes in MMAE was significantly higher than that in BHS (OW: 10.9% vs 3.2%, P=0.021; PSM: 10.7% vs 0%, P=0.027). Hematoma volume was an independent risk factor to predict the primary outcomes (adjusted OR, 1.02 (1.01–1.03), P=0.001). In the subgroup with hematoma volume 0.999). Moreover, patients benefited from standalone MMAE with shorter length of hospital stay (OW: P=0.011, PSM: P=0.001). However, in the subgroup with hematoma volume >98 mL, standalone MMAE showed a significantly higher rate of primary outcomes than BHS (OW: 23.5% vs 8.2%, P=0.049; PSM: 23.8% vs 0%, P=0.021). Conclusion: Given the advantage of its minimally invasive nature and low primary outcome rates when hematoma volume is 98 mL, standalone MMAE cannot be routinely recommended to replace BHS.
Funding Information
  • Shanghai Municipal Hospital Development Center (SHDC2022CRD032)
  • National Natural Science Foundation of China (82171313)
  • National Natural Science Foundation of China (82271338)
  • National Natural Science Foundation of China (82301491)
  • National Natural Science Foundation of China (82301492)
  • Noncommunicable Chronic Diseases–National Science and Technology Major Project (2023ZD0505200)
  • Noncommunicable Chronic Diseases–National Science and Technology Major Project (2026ZD0554904)

This publication has 23 references indexed in Scilit: